End-Stage Renal Disease (ESRD) Market to Witness Significant Growth by 2034, Driven by Rising CKD and Diabetes Prevalence | DelveInsight

DelveInsight's "End-Stage Renal Disease Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of End-Stage Renal Disease, historical and forecasted epidemiology, as well as the End-Stage Renal Disease therapeutics market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Explore the intricate details of the End-Stage Renal Disease Market Report @ https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Key Takeaways from the End-Stage Renal Disease Market Report
• In September 2026, CSL Behring announced result of A Phase 2b / 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis.
• In July 2026, Laminate Medical Technologies announced result of Postmarket Surveillance, Prospective, Multicenter, Randomized, Controlled Study Evaluating the Performance of VasQ for Its Intended Use.
• The End-Stage Renal Disease Market Size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• According to the Centers for Disease Control and Prevention (2022), as of December 31, 2018, approximately 0.7 million patients (785,883) were being treated for End-Stage Renal Disease in the United States, giving a point prevalence of 2,382 per million population; the prevalence of dialysis treatment was 1,685 per million, while the prevalence of functioning kidney transplant was 696 per million.
• A nationwide survey by the Japanese Society for Dialysis Therapy revealed a higher prevalence of End-Stage Renal Disease in men than in women, and women appear to be somewhat protected from developing the condition; the mean age at the start of dialysis is also lower in men than in women.
• The End-Stage Renal Disease Companies include Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, and others.
• Emerging End-Stage Renal Disease therapies under the late and mid-stage of development include AB002 (Aronora) and MK-2060 (Merck).

Request for unlocking the Sample Page of the End-Stage Renal Disease Market Insights Report @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

What is End-Stage Renal Disease?
End-stage renal disease (ESRD) is the final stage of chronic kidney disease, where the kidneys lose nearly all their ability to function. Patients with ESRD require renal replacement therapy, such as hemodialysis, peritoneal dialysis, or kidney transplantation, to survive. The condition often results from diabetes, hypertension, or other chronic kidney disorders, and can lead to severe complications affecting the cardiovascular system, bone health, and overall quality of life. Early detection and management of underlying conditions are crucial to slow disease progression and improve outcomes.

End-Stage Renal Disease Diagnosis
Diagnosis of end-stage renal disease (ESRD) involves assessing kidney function through blood tests (measuring serum creatinine and estimating glomerular filtration rate, eGFR) and urine tests to detect proteinuria or other abnormalities. Imaging studies, such as ultrasound devices or CT scans, may be used to evaluate kidney size and structure. ESRD is typically diagnosed when kidney function declines to less than 15% of normal, indicating the need for renal replacement therapy like dialysis or transplantation. Regular monitoring of patients with chronic kidney disease is essential for early detection and timely intervention.

Download the report to understand which factors are driving End-Stage Renal Disease epidemiology trends @ https://www.delveinsight.com/report-store/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

End-Stage Renal Disease Epidemiology Segmentation in the 7MM
• Total Diagnosed Prevalent Cases of End-Stage Renal Disease in the 7MM
• Gender-specific Diagnosed Prevalent Cases of End-Stage Renal Disease in the 7MM
• Cause-specific Diagnosed Prevalent Cases of End-Stage Renal Disease in the 7MM
• Treated Cases of End-Stage Renal Disease in the 7MM

Country-Wise End-Stage Renal Disease Epidemiology
The epidemiology segment provides End-Stage Renal Disease epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, covering historical and current patient pools as well as forecasted trends from 2020 to 2034.

End-Stage Renal Disease Marketed Drugs
The end-stage renal disease (ESRD) market includes drugs primarily used to manage complications associated with kidney failure and dialysis. Key marketed therapies address anemia (erythropoiesis-stimulating agents and iron supplements), mineral and bone disorders (phosphate binders, vitamin D analogs, and calcimimetics), and cardiovascular risks. While dialysis and transplantation remain the core treatment approaches, these supportive medications play a critical role in improving patient outcomes, reducing complications, and enhancing quality of life in ESRD patients.

End-Stage Renal Disease Pipeline Analysis
• AB002: Aronora
AB002 (E-WE thrombin) is a first-in-class protein C activator enzyme, designed to act in part by increasing the surface concentration of the anticoagulant, profibrinolytic, and cytoprotective enzyme, endogenous activated protein C (APC), at the site of developing blood clots via targeted cellular delivery. This unique mechanism of action allows AB002 to target cell-rich pathological blood clots (thrombi) without disabling vital hemostasis.

• MK-2060: Merck
MK-2060 is a novel inhibitor of Factor XI being investigated for the prevention of thrombosis in patients with end-stage renal disease. Administered intravenously, MK-2060 is designed to work through a dual mechanism of action, both blocking the activation of Factor XI as well as the downstream activity of the activated protein.

End-Stage Renal Disease Companies
Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc, Becton, Dickinson and Company, and others

To know more about End-Stage Renal Disease companies working in the treatment market, visit @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

End-Stage Renal Disease Market Outlook
The End-Stage Renal Disease market outlook helps build a detailed comprehension of the historic, current, and forecasted End-Stage Renal Disease market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology. This segment gives a thorough detail of the End-Stage Renal Disease market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, and their impact on the market and the view of key opinion leaders. According to DelveInsight, the End-Stage Renal Disease market in the 7MM is expected to witness a major change over the study period 2020-2034.

Scope of the End-Stage Renal Disease Market Report
• Study Period: 2020 to 2034
• Forecast Period: 2024-2034
• Geographies Covered: The US, EU4 (Germany, France, Italy, and Spain) and UK, Japan
• End-Stage Renal Disease Market: Total Market Size, Market Size by Therapies, Market Size by Class
• End-Stage Renal Disease Companies: Medtronic PLC, B. Braun SE, Asahi Kasei Medical Co. Ltd, Cantel Medical (STERIS), Nikkiso Co. Ltd, Nipro Corporation, Fresenius SE & Co. KGaA, Baxter International Inc, Becton, Dickinson and Company, and others
• End-Stage Renal Disease Epidemiology Segmentation: Total Diagnosed Prevalent Cases, Gender-specific Diagnosed Prevalent Cases, Cause-specific Diagnosed Prevalent Cases, and Treated Cases of End-Stage Renal Disease in the 7MM

To know more about the End-Stage Renal Disease treatment market, visit @ https://www.delveinsight.com/sample-request/end-stage-renal-disease-esrd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=akpr

Table of Content
1. Key Insights
2. Executive Summary of End-Stage Renal Disease
3. Competitive Intelligence Analysis for End-Stage Renal Disease
4. End-Stage Renal Disease: Market Overview at a Glance
5. End-Stage Renal Disease: Disease Background and Overview
6. Patient Journey
7. End-Stage Renal Disease Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. End-Stage Renal Disease Unmet Needs
10. Key Endpoints of End-Stage Renal Disease Treatment
11. End-Stage Renal Disease Marketed Products
12. End-Stage Renal Disease Emerging Therapies
13. End-Stage Renal Disease: Seven Major Market Analysis
14. Attribute Analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of End-Stage Renal Disease
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Company Name: DelveInsight Business Research LLP
Contact Person: Abhishek kumar
Email: info@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com

About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

This release was published on openPR.